Panel · Use case · Brand & Marketing

Promotional Claim Red Team.

LiveRed Team Review

Stress-test a promotional claim from compliance, regulatory, medical information and brand angles before review.

Plan under testA comparative superiority claim

AnglesCompliance, regulatory, medical, brand

ReaderBrand and compliance leads

Not askedLegal advice

DepthStandard, four seats

Promotional Claim Red Team is a ready-made use case for Brand & Marketing. It ships under the Red Team Review template.

For brand and compliance leads. You get the position under test, a verdict, the challenges by angle, which survive, what would have to be true and where the claim is weakest. This is context for review, not legal advice. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

Where does a comparative superiority claim for a prescription medicine fail, before it goes to promotional review?

Who attacks

In the United States, prescription drug advertising must not be false or misleading, and comparative claims must be supported. The red team checks each element of the claim.

Seat	How it attacks	What it works from
Global Commercial Compliance Officer	Whether the claim is supported, fairly balanced and consistent with the labeling.^{1Code of Federal Regulations. 21 CFR 202.1: Prescription-drug advertisements.,2U.S. Food and Drug Administration. Office of Prescription Drug Promotion (OPDP).}	21 CFR 202.1 and agency promotion guidance.
Regulatory Strategist	Whether the label supports the comparison and which studies the review record contains.^{1Code of Federal Regulations. 21 CFR 202.1: Prescription-drug advertisements.}	The approved labeling.
Medical Information Services Master	Whether the underlying data can be provided on request and whether the data are current.	Publications and enquiry practice.
Global Brand Lead	How the claim will be read by prescribers and what they will infer beyond it.	Message testing.

What the red team does

Head-to-head evidence is the usual test. A superiority claim needs a comparison designed to show it. The red team separates a claim supported by a head-to-head trial from one inferred from indirect comparison.^{1Code of Federal Regulations. 21 CFR 202.1: Prescription-drug advertisements.}

What the audience infers. A claim can be true and still mislead through what it implies. The report states the likely inferences and which seat flagged them.^{2U.S. Food and Drug Administration. Office of Prescription Drug Promotion (OPDP).}

Weakest point. The element of the claim most likely to be challenged in promotional review.

Recommended length

Standard

Four angles can break this plan. Standard depth gives each a seat, scores the challenges and lists mitigations and tripwires in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the red team tests

The red team lists the assumptions the plan relies on and says what would break each. Examples for this plan:

The head-to-head study is in the approved labeling.
The comparison population matches the prescribed population.
The claim will not be read as applying to other indications.

Standards, guidance and sources

Rules

21 CFR 202.1, Prescription-drug advertisements.^{1Code of Federal Regulations. 21 CFR 202.1: Prescription-drug advertisements.}
FDA Office of Prescription Drug Promotion.^{2U.S. Food and Drug Administration. Office of Prescription Drug Promotion (OPDP).}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any comparison that rests on indirect evidence, any claim whose study is not in the label, and any wording that implies more than the data show.

What arrives

The position under test
Verdict
The challenges, by angle
Which challenges survive
The pre-mortem
What would have to be true
Mitigations and tripwires
Where the position is weakest

What it will not do

It stays adversarial and does not defend the plan. It is a stress test by AI specialists and not a vote of human experts, and the decision stays with you.

This is context for your review, not legal advice, and it does not replace the company’s promotional review.

It does not defend the plan. Defenses appear only as the status of an attack.

It does not invent an attack. Each challenge rests on a cited fact or is marked as a gap.

It is not a vote of human experts. Every seat is an AI specialist, and the report says so.

References

[1] Code of Federal Regulations. 21 CFR 202.1: Prescription-drug advertisements. Known from the eCFR; the text was not read in this pass.
[2] U.S. Food and Drug Administration. Office of Prescription Drug Promotion (OPDP). Known from FDA’s site; not read in full.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.